MARKET

CNTB

CNTB

Connect Biopharma Holdings Ltd
NASDAQ
2.690
-0.210
-7.24%
Opening 11:45 03/31 EDT
OPEN
2.780
PREV CLOSE
2.900
HIGH
2.998
LOW
2.640
VOLUME
189.39K
TURNOVER
--
52 WEEK HIGH
3.820
52 WEEK LOW
0.5100
MARKET CAP
150.38M
P/E (TTM)
-3.7017
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)
TipRanks · 1h ago
Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG
Dow Jones · 5h ago
Buy Rating on CNTB Driven by Rademikibart’s Rapid Lung Function Gains, COPD Differentiation, and Strengthened Cash Runway
TipRanks · 5h ago
BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target
Benzinga · 5h ago
Buy Rating on CNTB: Fast-Acting Rademikibart Data Underscore Differentiation and Long-Term Respiratory Opportunity
TipRanks · 5h ago
BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
Reuters · 23h ago
Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK)
TipRanks · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike
Reuters · 1d ago
More
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Webull offers Connect Biopharma Holdings Ltd (ADR) stock information, including NASDAQ: CNTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTB stock methods without spending real money on the virtual paper trading platform.